Grit Biotechnology Completes RMB 400 Million Series B Financing to Advance TIL Therapy Pipeline

Zhuhai Grail Bio Co., Ltd. ("Grail Bio") recently completed a 400 million yuan Series B financing round. This round was led by a fund under CICC Capital, with participation from Qianhai Ark, LIANDO, Yantai Yuanhe Equity Investment Fund Management Co., Ltd., He Fangtian Partnership Enterprise, as well as existing investors Sherpa Healthcare Partners, Decheng Capital, and Matrix Partners China. The funds will be used to support the development of the company's Tumor Infiltrating Lymphocyte (TIL) therapy pipeline.

Grail Bio was founded in 2019 as an innovative pharmaceutical company focused on tumor immunotherapy and cell treatment, with a research and development pipeline represented by TIL drugs. The company possesses internationally leading technical reserves and industry resources. Its self-developed GT101 injection is the first TIL drug in China to be approved for clinical trials and will soon enter the pivotal Phase II clinical trial. Grail Bio is currently accelerating the clinical progress of its leading pipeline product, GT101, and aims to achieve commercialization as soon as possible.